RyR2 inhibition with dantrolene is antiarrhythmic, prevents further pathological remodeling, and improves cardiac function in chronic ischemic heart disease
Diastolic Ca2+ leak due to cardiac ryanodine receptor (RyR2) hyperactivity has been widely documented in chronic ischemic heart disease (CIHD) and may contribute to ventricular tachycardia (VT) risk and progressive left-ventricular (LV) remodeling. Here we test the hypothesis that targeting RyR2 hyperactivity can suppress VT inducibility and progressive heart failure in CIHD by the RyR2 inhibitor dantrolene.
Source: Journal of Molecular and Cellular Cardiology - Category: Cytology Authors: Jeffrey Schmeckpeper, Kyungsoo Kim, Sharon A. George, Dan Blackwell, Jaclyn A. Brennan, Igor R. Efimov, Bjorn C. Knollmann Source Type: research
More News: Cardiology | Cytology | Heart | Heart Disease | Heart Failure | Hyperactivity | Ventricular Tachycardia